[go: up one dir, main page]

WO1995031552A3 - Human papilloma virus inhibition by a hairpin ribozyme - Google Patents

Human papilloma virus inhibition by a hairpin ribozyme

Info

Publication number
WO1995031552A3
WO1995031552A3 PCT/US1995/006016 US9506016W WO9531552A3 WO 1995031552 A3 WO1995031552 A3 WO 1995031552A3 US 9506016 W US9506016 W US 9506016W WO 9531552 A3 WO9531552 A3 WO 9531552A3
Authority
WO
WIPO (PCT)
Prior art keywords
human papilloma
papilloma virus
hairpin ribozyme
virus inhibition
hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/006016
Other languages
French (fr)
Other versions
WO1995031552A2 (en
Inventor
Arnold Hampel
Joseph Dipaolo
Andrew Siwkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northern Illinois University
US Department of Health and Human Services
Government of the United States of America
Original Assignee
Northern Illinois University
US Department of Health and Human Services
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northern Illinois University, US Department of Health and Human Services, Government of the United States of America filed Critical Northern Illinois University
Priority to AU25887/95A priority Critical patent/AU712160B2/en
Priority to JP7529813A priority patent/JPH10500307A/en
Priority to DE69533694T priority patent/DE69533694T2/en
Priority to EP95920437A priority patent/EP0759992B1/en
Priority to AT95920437T priority patent/ATE280830T1/en
Priority to MX9605514A priority patent/MX9605514A/en
Publication of WO1995031552A2 publication Critical patent/WO1995031552A2/en
Publication of WO1995031552A3 publication Critical patent/WO1995031552A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Synthetic ribozymes, i.e. ribozymes including a hairpin portion, binding sites for binding to a human papilloma virus (HPV) after viral base 419 or 434, respectively, and cleavage sites for cleaving HPV virus are disclosed. The invention also includes a diagnostic assay for determining the presence of HPV-16 in tissues based on PCR amplification.
PCT/US1995/006016 1994-05-13 1995-05-15 Human papilloma virus inhibition by a hairpin ribozyme Ceased WO1995031552A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU25887/95A AU712160B2 (en) 1994-05-13 1995-05-15 Human papilloma virus inhibition by a hairpin ribozyme
JP7529813A JPH10500307A (en) 1994-05-13 1995-05-15 Inhibition of human papillomavirus by hairpin ribozymes
DE69533694T DE69533694T2 (en) 1994-05-13 1995-05-15 INHIBITION OF HUMAN PAPILLOMA VIRUS BY "HAIRPIN RIBOZYME"
EP95920437A EP0759992B1 (en) 1994-05-13 1995-05-15 Human papilloma virus inhibition by a hairpin ribozyme
AT95920437T ATE280830T1 (en) 1994-05-13 1995-05-15 INHIBITION OF HUMAN PAPILLOMAVIRUS BY ßHAIRPIN-RIBOZYMES
MX9605514A MX9605514A (en) 1995-03-21 1995-05-15 Human papilloma virus inhibition by a hairpin ribozyme.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24266594A 1994-05-13 1994-05-13
US08/242,665 1994-05-13
US08/410,005 US5683902A (en) 1994-05-13 1995-03-21 Human papilloma virus inhibition by a hairpin ribozyme

Publications (2)

Publication Number Publication Date
WO1995031552A2 WO1995031552A2 (en) 1995-11-23
WO1995031552A3 true WO1995031552A3 (en) 1996-01-11

Family

ID=26935239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/006016 Ceased WO1995031552A2 (en) 1994-05-13 1995-05-15 Human papilloma virus inhibition by a hairpin ribozyme

Country Status (2)

Country Link
US (1) US5683902A (en)
WO (1) WO1995031552A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002300399C1 (en) * 1997-09-05 2006-08-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Human papilloma virus inhibition by anti-sense oligonucleotides
US6084090A (en) * 1997-09-05 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus anti-sense oligonucleotides
CA2365901A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
EP1133988A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
AU2001296846B2 (en) 2000-10-12 2007-07-05 University Of Rochester Compositions that inhibit proliferation of cancer cells
EP1572168B1 (en) 2002-02-06 2010-05-26 Vicor Technologies, Inc. Anti-infarction molecules
US20060099219A1 (en) * 2002-04-24 2006-05-11 Universite Libre De Bruxelles Mutated hpv-16e7 polypeptide, pharmaceutical composition comprising it and its preparation process
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
CN1780920B (en) * 2003-05-12 2012-03-28 波多玛克制药有限公司 Gene expression inhibitor
WO2004108623A2 (en) * 2003-06-04 2004-12-16 Verline Inc. A method and apparatus of curing concrete structures
JP5562521B2 (en) 2005-02-02 2014-07-30 ザ ユーエービー リサーチ ファンデーション Agents and methods relating to reducing resistance to apoptosis-inducing death receptor agonists
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against cd38 for treatment of multiple myeloma
US7476733B2 (en) 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
WO2006116294A1 (en) * 2005-04-25 2006-11-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A single ribozyme to catalyze both trimming and trans-acting catalysis
US20100255026A1 (en) * 2005-10-06 2010-10-07 Michael Jason Stump Methods and compositions relating to anthrax spore glycoproteins as vaccines
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2395076A1 (en) 2005-10-14 2011-12-14 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US20100190689A1 (en) 2006-09-21 2010-07-29 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
EP2104509A4 (en) 2006-12-11 2010-03-24 Univ Utah Res Found COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGICAL ANGIOGENESIS AND VASCULAR PERMEABILITY
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8501912B2 (en) 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
EP2288922B1 (en) 2008-05-08 2016-08-17 University of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
EP2370080A1 (en) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
BR112017001860A2 (en) 2014-07-31 2018-02-27 Uab Research Foundation synthetic peptide, pharmaceutical composition, methods, dosage regimen, and monoclonal antibody
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
MX2019001364A (en) 2016-08-03 2019-08-01 H Lee Moffitt Cancer Ct & Res Tlr9 targeted therapeutics.
US12016314B2 (en) 2017-09-08 2024-06-25 Ohio State Innovation Foundation MicroRNA inhibitor therapy in systemic lupus erythematosus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023569A1 (en) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023569A1 (en) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEONG, C. ET AL.: "Solution structure of an unusually stable RNA hairpin, 5'GGAC(UUCG)GUCC", NATURE, vol. 346, 16 August 1990 (1990-08-16), LONDON GB, pages 680 - 682 *
EVANS, C. ET AL.: "REGULATION OF HUMAN PAPILLOMA VIRUS 16 HPV16 DNA POSITIVE CERVICAL EPITHELIAL CELL SENSITIVITY TO LAK LYMPHOCYTE LYSIS BY TREATMENT WITH CISPLATIN AND THE CYTOKINES GAMMA INTERFERON OR LEUKOREGULIN.", 83RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN DIEGO, CALIFORNIA, USA, MAY 20-23, 1992. & PROC AM ASSOC CANCER RES ANNU MEET 33 (0). 1992. 307 *
HE, Y.-K. ET AL.: "IN-VITRO CLEAVAGE OF HPV16 E6 AND E7 RNA FRAGMENTS BY SYNTHETIC RIBOZYMES AND TRANSCRIBED RIBOZYMES FROM RNA-TRIMMING PLASMIDS.", FEBS (FED EUR BIOCHEM SOC) LETT 322 (1). 1993. 21-24 *

Also Published As

Publication number Publication date
WO1995031552A2 (en) 1995-11-23
US5683902A (en) 1997-11-04

Similar Documents

Publication Publication Date Title
WO1995031552A3 (en) Human papilloma virus inhibition by a hairpin ribozyme
WO1999049807A3 (en) A device and method for performing a biological modification of a fluid
ID22349A (en) DEGREE FROM 8-AZABISIKLO [3.2.1] OKTANA-, 8-AZABISIKLO [3.2.1] OKT-6-ENA-, 9-AZABISIKLO- [3.3.1] NONANA-, 9-AZA-3-OKSABISIKLO [3.3. 1] NONANA- AND 9-AZA-3-TIOBISIKLO [3.3.1] NONANA, IT'S MAKING AND USE AS AN INSECTICIDE
EP1149841A3 (en) Process for the production of 6B,7B;15B,16B-dimethylene-5B-hydroxy-3-oxo-17alpha-androstane-21,17-carbolactone
ITTO950367A0 (en) RECOMBINANT PRRSV PROTEINS, DIAGNOSTIC KITS AND VACCINES CONTAINING SUCH RECOMBINANT PRRSV PROTEINS.
EP0402132A3 (en) Method for the detection of human papilloma-virus
DK1021722T3 (en) Improvements in or related to screening for papillomaviruses
WO2002052041A3 (en) 5' nuclease nucleic acid amplification assay having an improved internal control
TR199501580A2 (en) The method of pulverizing and / or dispersing agents by physico-chemical separation, the factors obtained and their usage areas.
WO2001016377A3 (en) Diagnostics and therapeutics for osteoporosis
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
Hoffman Surface modification of polymers
CA2112096A1 (en) Dna sequences of the human papillomavirus type 42 and diagnostic application thereof
MX9605514A (en) Human papilloma virus inhibition by a hairpin ribozyme.
EP1327683A3 (en) Human papilloma virus inhibition by a hairpin ribozyme
EP0690124A3 (en) Alcohol removal procedure for alcoholic beverages and low alcoholic grading beverages obtained thereby
FI893683A0 (en) Human papillomavirus type 57, its isolated DNA and their use
WO1999004029A3 (en) A swine hepatitis e virus and uses thereof
WO1997008531A3 (en) Detection of hepatitis gb virus genotypes
WO1993002217A3 (en) Oligonucleotide probes for type determination and detection of human papillomaviruses
EP0948351A4 (en) SYNTHETIC PARTICLES OF HPV16 TYPE VIRAL NATURE
AU1457300A (en) Dna replication-regulating genes, antibodies thereto and diagnostic applicationsthereof
WO2000007464A3 (en) Agent for stabilizing foodstuffs and cosmetic agents, and a method for the production thereof
WO2001003717A3 (en) Methods of inducing cell death
吕百达 et al. Changes of super-Gausian beams upon propagation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1996/005514

Country of ref document: MX

Ref document number: 2190102

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1996 737454

Country of ref document: US

Date of ref document: 19961113

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1995920437

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995920437

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1995920437

Country of ref document: EP